Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (NASDAQ: ICLR) is a clinical research organisation headquartered in Dublin, Ireland, operating in the research and development in biotechnology industry. This news page focuses on company announcements and updates that relate to its clinical research activities, financial performance and corporate developments.
ICON’s news releases commonly cover quarterly financial results, including revenue, net income, adjusted EBITDA and related non‑GAAP measures. These updates often discuss business wins, book‑to‑bill ratios, cash generation and capital allocation decisions such as share repurchase activity, as reflected in the company’s second and third quarter 2025 results announcements.
Investors and industry observers can also find news about ICON’s participation in investor and healthcare conferences. The company regularly announces presentations at events such as global healthcare conferences and growth stock conferences, as well as the scheduling of earnings conference calls and webcasts. These items provide insight into how ICON communicates its strategy and performance to the market.
Corporate governance and leadership changes are another key news category. For example, ICON has announced a CEO transition, detailing succession planning and board decisions. The company also publishes the results of its annual general meeting, including shareholder votes on director elections, auditor ratification and share authorisations.
In addition, ICON highlights recognition of its clinical research capabilities, such as independent benchmarking reports that assess its performance in phase 1 clinical trials. News may also include updates on specific research programmes, such as vaccine study updates noted in its filings. For ongoing visibility into ICON plc’s operations, financial reporting and role as a clinical research organisation, this news feed aggregates company-issued information in one place.
ICON plc (NASDAQ: ICLR) reported strong Q4 2020 results, with record net business wins of $1,080 million and a book-to-bill ratio of 1.42, increasing backlog to over $9.7 billion (up 13% YoY). Revenue grew by 5% to $760 million, and EPS rose to $1.90 (up 4%). For 2021, revenue guidance is set at $3,200 - $3,300 million, reflecting a 14% - 18% increase, with EPS guidance of $8.10 - $8.50 (24% - 30% increase). Despite the pandemic's challenges, ICON remains focused on safety and continues to manage over 120 COVID-19 trials. Full-year revenue declined slightly by 0.3% to $2,797 million.
ICON plc (NASDAQ: ICLR) has announced a definitive agreement to acquire PRA Health Sciences (NASDAQ: PRAH) for approximately $12 billion. The acquisition will involve $80 in cash and 0.4125 shares of ICON stock per PRA share, representing a 30% premium from PRA's closing price on February 23, 2021. The merger aims to enhance clinical trial execution and increase efficiency, delivering an estimated $150 million in cost synergies. The deal is expected to close in Q3 2021, subject to regulatory approvals.
Cytocom has submitted an IND application to the FDA for a Phase 2 clinical trial of CYTO-205, aimed at evaluating its efficacy against COVID-19. Preclinical studies indicate CYTO-205 may inhibit coronavirus strain 229E replication in lung cells. The trial, commencing in Q2 2021, targets high-risk adults with mild COVID-19 infection. Additionally, Cytocom partnered with ICON plc to manage the Phase 3 trial for CYTO-201, its lead candidate for Crohn's disease. The company emphasizes the need for effective COVID-19 therapies despite vaccine availability.
ICON plc (NASDAQ: ICLR) has launched two new digital solutions, FIRECREST Safety Letters and FIRECREST Site Question Management, enhancing clinical research efficiency. The integrated FIRECREST suite allows for electronic acknowledgment of safety letters with compliance tracking. It simplifies safety letter management, enabling quick sponsor reconciliation and ensuring regulatory compliance. The Site Question Management solution streamlines medical query handling, improving response times. With 540,000 users across 233 indications, these innovations support top pharmaceutical companies in navigating complex safety reporting.
ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development, announced that Dr. Steve Cutler, CEO, and Mr. Brendan Brennan, CFO, will present at the 39th Annual JP Morgan Healthcare Conference on January 12, 2021, at 7:30 AM ET. The presentation will cover strategic developments in drug and device commercialization. Interested parties can access updates and links to live webcasts on the Investor Relations section of their website under 'Events'. As of September 30, 2020, ICON employed approximately 15,250 people across 94 locations worldwide.
ICON plc (NASDAQ: ICLR) announced the release of its inaugural Environmental, Social and Governance (ESG) Report, showcasing its ESG policies and commitments, as well as progress made in 2019. This report is part of ICON's strategy to enhance transparency and accountability in its operations. The ESG report is accessible here. As of September 30, 2020, ICON employed approximately 15,250 individuals across 94 locations in 40 countries, solidifying its global presence in pharmaceutical and biotechnology sectors.
ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at two upcoming virtual healthcare conferences. The first is the 29th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2020, starting at 08:45 ET, followed by the Evercore ISI HealthCONx Conference on December 2, 2020, at 11:20 ET. Links to live webcasts and any changes will be updated in the Investor section of ICON's website. As of September 30, 2020, ICON employed approximately 15,250 staff across 94 locations globally.
ICON plc (NASDAQ: ICLR) reported robust financial results for Q3 2020, achieving a record $990 million in net business wins, with a book-to-bill ratio of 1.41. Despite a 1.2% year-on-year decline in revenue to $701.7 million, the company raised its 2020 revenue guidance to $2,750 million - $2,810 million. Operational income for the quarter was $108.4 million, and the net income was $91.6 million. The company reported net cash of $359.8 million, up from $244.0 million in Q2 2020. ICON is well-positioned to leverage COVID-19 opportunities, managing over 100 trials related to the pandemic.
Summary not available.